Omarigliptin (MK-3102) Manufacturer For Hypoglycemic Agents CAS NO.1226781-44-7

Min.Order Quantity:: 10 Gram

Purity:: 99%min

Port:: ShangHai

Payment Terms:: T/T,MoneyGram

Add to Inquiry Cart

Product Details

Keywords

99%min Omarigliptin (MK-3102)
Omarigliptin (MK-3102) Manufacturer
For Hypoglycemic Agents

Quick Details

ProName: Omarigliptin (MK-3102) Manufacturer Fo...
CasNo: 1226781-44-7
Molecular Formula: C17H20F2N4O3S
Appearance: White Powder
Application: For Pharmaceutical Raw Materials
DeliveryTime: 2-4 days after confirmed your payments
PackAge: 100g/ bag, 2 kg/ bag, 25kg/ carton or ...
Port: ShangHai
ProductionCapacity: 1000 Metric Ton/Month
Purity: 99%min
Storage: Dry and cool place
Transportation: By DHL, TNT, FedEx, HKEMS, UPS, Etc
LimitNum: 10 Gram

Superiority

advantages:

hubei xinrunde chemical co., ltd is a renowned pharmaceutical manufacturer. we can offer high quality products at competitive price in quick delivery with 100% custom pass guaranteed. never stop striving to offer our best service is our philosophy. we have flexible and untraceable payment terms. as a leading manufacture, our products have been exported to germany, norway, poland, finland, spain, uk, france, russia, usa, brazil, mexico, australia, japan, korea, thailand, indonesia, uruguay and many other countries.

1. quality.every batch of steroid powders have tobetested by our qc(quality control) before they are allowed to sell.

2 . delivery we have stock, so we can delivery quickly at the very day when receive the payment. within 24 hours after receiving the payment lead time 4 or 7 days.

3 . discreet package safelyand professionally disguised package guaranteed. for your safety and to insure delivery all products will be packed in a discreet way to prevent any suspicions, no steroids related name will appear on the parcels. high successful delivery rate

4 . warm after-sale service any of your question would be solved for the first as soon as possible.

Details

omarigliptin (mk-3102) basic information

oral hypoglycemic agents clinical evaluation market expectation

product name:	omarigliptin (mk-3102)
synonyms:	mk-3102;(2r,3s,5r)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2h,4h,6h)-yl)tetrahydro-2h-pyran-3-amine;mk-3012;(2s,3r,5s)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]tetrahydro-2h-pyran-3-amine (mk-3102 enantiomer);(2r,3s,5r)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]tetrahydro-2h-pyran-3-amine;omarigliptin;omarigliptin (mk-3102);2r,3s,5r)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]tetrahydro-2h-pyran-3-amine mk3102
cas:	1226781-44-7
mf:	c17h20f2n4o3s
mw:	398.43
einecs:	1592732-453-0
product categories:	api;inhibitors
mol file:	1226781-44-7.mol

omarigliptin (mk-3102) usage and synthesis

oral hypoglycemic agents	omarigliptin (mk-3102) is an oral hypoglycemic agent of super long-lasting dipeptidyl peptidase-4 (dpp-4) developed by merck & co., usa. it is administered orally once a week, being able to produce sustained dpp-4 inhibition with a new mechanism of lowering blood sugar. meanwhile, it does not increase body weight and not cause hypoglycemia and edema. its mechanism of action is through inhibiting the degrading of the in vivo dipeptidyl peptidase-4 (dpp-4) on the glp-1, prolonging the action time of glucagon-like peptide-1 (glp-1), thereby increasing the blood concentration of the endogenous glp-1 and gip, and ultimately improving blood glucose control. glp-1 is a class of incretin, belonging to a moderate-length straight-chain peptide hormone with insulin secretion promoting effect generated in the intestine. its action features include: merely postprandial production, promoting insulin secretion by islet β-cells and further lowing the blood sugar level but without triggering the hypoglycemia; it can inhibit the pancreatic α cells from secreting the glucagon; delay the gastric emptying which is good for the postprandial blood glucose control; it can cause inhibition of intestinal secretion of lipoproteins and may reduce the postprandial hyperglycemia which is risk factors for cardiovascular disease, thus playing a heart protection effect. omarigliptin is a kind of dpp-4 inhibitor oral hypoglycemic agents administrated once weekly, improving the drug compliance. poor adherence to medication is a common problem in clinical practice, particularly in chronic asymptomatic diseases such as type 2 diabetes, dyslipidemia, and hypertension. for the patients of type ii diabetes, improving the adherence to medication is critical to maintaining good glycemic control during long-term treatment, thereby preventing the development of type 2 diabetes and the development and progression of complications. on september 19, 2014, merck published the first data on the phase iii clinical development of omarigliptin in the treatment of type 2 diabetes at the 50th annual european diabetes association (easd) annual meeting. compared with placebo, omarigliptin can significantly reduce the hba1c levels, meanwhile being able to achieve equal efficacy and tolerability to a 50-mg daily dose of the dpp-4 inhibitor januvir (sigma). in december 2014, merck has submitted an experimental new drug application (nda) of the hypoglycemic drug omarigliptin to the japanese pharmaceutical and medical device agency (pmda), marking the world's first regulatory application.
clinical evaluation	(1) pharmacodynamic properties. the inhibitory activity of omarigliptin on dpp-4 (c50 = 1.6 nm, k1 = 0.8 nm) is stronger than that of sitagliptin (ic50 = 18 nm). (2) high selectivity to dpp-4. dpp has many subtypes from 1-9, of which the inhibition constant of dpp-8 and dpp-9 are often related with the toxic effects of drugs. two weeks of rat studies have shown that inhibition of dpp-8 and dpp-9 can lead to increased hair loss, thrombocytopenia, anemia, splenomegaly and even death cases in rats. in acute dog toxicity studies, inhibition resulted in bloody diarrhea in dogs. in vitro studies have shown that omarigliptin is very specific for dpp-4 inhibition and has very low activity against the remaining proteases (including qpp, fap, fef, dpp8 and dpp9) with ic50> 67 μm and thus does not produce the above-mentioned side effects. (3) in the aspect of pharmacokinetics, the most significant feature of omarigliptin is a long half-life of up to 63h while the value for sitagliptin is 12.4h, for vildagliptin is 2-3 h and for saxagliptin in the parent body is 2.5 h. this means that omarigliptin only needs to be taken once a week to achieve better glycemic control effect. (4) in the aspect of usage range, renal insufficiency has effects on the in vivo exposure level and clearance rate of the omarigliptin, so we may need to adjust the dosage and usage of the drug. this may be similar to other dpp-4 inhibitors such as sitagliptin, vildagliptin and saxagliptin. comparatively, the advantage of omarigliptin is obvious, which has excellent pk/pd, efficacy and safety with excellent potential during the clinical treatment.
market expectation	diabetes is caused by the effects of genetic factors, immune dysfunction, microbial infection and toxins, free radical toxins, mental factors, and various kinds of pathogenic factors on the body that lead to islet dysfunction, insulin resistance, further causing a series metabolic disorders of sugar, protein, fat, water and electrolytes. it is clinically mainly characterized by the high blood sugar. in typical cases, there may be polyuria, polydipsia, more food, weight loss and other performance, namely "three polys and one little" symptoms, blood sugar, once not controlled well, will lead to poor diabetes complications, leading to the failure of lesions in kidney, eye, foot and other parts and can’t be cured. china is a big country of diabetes. according to the latest research results, in the samples of china's 18-year-old and adult, the estimated prevalence of diabetes was 11.6%, about 113.9 million people. the pre-diabetes (igt) prevalence rate in chinese adults is about 50.1%, namely, half of the people is the reserve of diabetes. this figure is very alarming, indicates that china's diabetes situation is very serious. dpp-4 inhibitors are the host spots at both home and abroad in recent years. the number listed abroad has already reached 7. there are also a number of domestic 1.1 class novel drug of independent research and development having obtained clinical approval documents. the first marketed dpp-4 inhibitor is sitagliptin, with sales currently being $ 4 billion and is expected to reach $ 7.8 billion by 2018. the pharmacological effects, clinical evaluation, indications, and market prospects of oral hypoglycemic agents, omarigliptin, are compiled by the editor, tontong of the chemicalbook (2015-09-22).